Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A.
Peripheral-blood mononuclear cells from renal-allograft patients receiving cyclosporin A (CSA) were tested for their ability to produce T cells cytotoxic for EB-virus-infected B-cell targets in culture and compared with those from healthy seropositive subjects. Whereas in the control cultures the proliferating foci of EB-virus-transformed B cells regressed after 2 weeks, no such regression was seen in cultures from CSA-treated patients. These results indicate that patients receiving CSA cannot mount a cytotoxic response to EB-virus-infected B cells in vitro. It is suggested that suppression of memory-T-cell proliferation contributes to the high incidence of lymphomas in CSA-treated renal-allograft recipients.
D000293:Adolescent; D000328:Adult; D001402:B-Lymphocytes / Q000382:microbiology; D002472:Cell Transformation, Viral; D002478:Cells, Cultured; D003524:Cyclosporins; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects*; D016030:Kidney Transplantation; D016403:Lymphoma, Large B-Cell, Diffuse / Q000209:etiology; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects*; D013997:Time Factors; D014184:Transplantation, Homologous
D003524:Cyclosporins; D010456:Peptides, Cyclic